September 15, 2022

ESMO Reactions: ADAURA

September 15, 2022

ESMO Reactions: ADAURA

Author

Osimertinib as adjuvant therapy in patients(pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

Abstract #LBA47: Masahiro Tsuboi presented two-year follow-up data of disease free survival (DFS) and recurrence patterns from the P3 ADAURA trial, which compared osimertinib(n=339) versus placebo (n=343) in patients with completely resectedEGFRm stage IBꟷIIIA NSCLC ± adjuvant CT.

Results: ContinuedDFS benefit was sustained with osimertinib vs placebo, consistent with the primary analysis. Median DFS was 65.8 mos vs 21.9 mos in osimertinib vs placebo arms, respectively. Fewer pts experienced local/regional and distant recurrence in osimertinib arm vsplacebo (27% vs 60%). Long-term safety profile consistent with known profile of osimertinib.

ADAURA Results 1

Adaura Result 2

Oncologist thought leaders cite that DFS remains very impressive for Osimertinib in early EGFRm NSCLC; however, several wonder whether the treatment is more preventative vs. curative

Several commentators are somewhat disappointed to not yet see overall survival (OS) data

A few oncologists mention a particular benefit in reducing CNS relapse

Adaura Result 3

Summary:

Two-year follow-up data from the ADAURA shows impressive disease-free survival benefit with osimertinib in completely resected EGFRm stage IBꟷIIIA NSCLC, particularly with respect to CNS. Based on KM curves, numerous commentators suspect the treatment may have a more preventative vs. curative effect; they seek OS data to clarify this question.

Synthesis by Opus Strategy, LLC.

Opus
Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.